WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its development of innovative ...
TScan Therapeutics, Inc. (NASDAQ:TCRX) shares are trading higher in the premarket session on Thursday. The firm announced a significant financing deal, entering into a securities purchase agreement ...
TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers. The company had ...
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) ...
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) ...
TScan Therapeutics announces $30 million investment from Lynx1 Capital Management for pre-funded warrants, extending cash runway into early 2027. TScan Therapeutics, Inc. has announced a securities ...
Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results